Rifampicin毎日と間欠治療症例の遠隔成績

概要

論文の詳細を見る
A follow-up study was performed on retreatment pulmonary tuberculosis patients who had shown negative conversion of sputum by daily or intermittent therapy with rifampicin for 6 months.<BR>Cavitary pulmonary tuberculosis cases with resistance to multiple drugs, but not having previously received either rifampicin or pyrazinamide were randomly divided into 3 gro ups: one group of 67 cases being administered rifampicin 450 mg daily, one group of 67 cases rifampicin 450 mg twice a week and one group of 69 cases rifampicin 900 mg twice a w eek. In all cases 1.5 g of pyrazinamide was administered daily. The background factors, as shown in Table 1, did not differ largely between the groups.<BR>At the end of 6 months treatment, the number of c ases whose sputum had been negative for tubercle bacilli for at least three consecutive months was 39 cases (58%) in the RFP 450 mg daily group, 24 cases (36%) in the RFP 450 mg twice weekly group and 40 cases (58%)in the RFP 900 mg twice weekly group (Table 2). These cases were then followed up for a maximum period of 3 years. As a general rule, subsequent chemotherapy was changed to a regimen not containing rifampicin, but in some cases the use of rifampicin was continued. Table 3 shows the duration of the follow-up period.
日本結核病学会の論文